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Background: The primary objective of this study is to identify novel copy number variations (CNVs) associated with
familial ankylosing spondylitis (AS). A customized genome-wide microarray was designed to detect CNVs and
applied to a multiplex AS family with six (6) affected family members. CNVs were detected using the built-in DNA
analytics aberration detection method-2 (ADM-2) algorithm. Gene enrichment analysis was performed to observe
the segregation. Subsequent validation was performed using real time quantitative fluorescence polymerase
reaction (QF-PCR). The frequency of copy number variation for the UGT2B17 gene was then performed on two
well-defined AS cohorts. Fisher exact test was performed to quantify the association.
Results: Our family-based analysis revealed ten gene-enriched CNVs that segregate with all six family members
affected with AS. Based on the proposed function and the polymorphic nature of the UGT2B17 gene, the UGT2B17
gene CNV was selected for validation using real time QF-PCR with full concordance. The frequency of two copies of
the UGT2B17 gene CNV was 0.41 in the Newfoundland AS cases and 0.35 in the Newfoundland controls (OR = 1.26
(0.99-1.59); p < 0.05)), whereas the frequency of two (2) copies of the UGT2B17 gene CNV was 0.40 in the Alberta
AS cases and 0.39 in the Alberta controls (OR = 1.05(95% CI: 0.83-1.33); p < 0.71)).
Conclusions: A genome-wide microarray interrogation of a large multiplex AS family revealed segregation of the
UGT2B17 gene CNV among all affected family members. The association of the UGT2B17 CNV with AS is particularly
interesting given the recent association of this CNV with osteoporosis and the proposed function as it encodes a
key enzyme that inhibits androgens. However, two copies of the UGT2B17 gene CNV were only marginally
significant in a uniplex AS cohort from Newfoundland but not in a uniplex AS cohort from Alberta.
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Ankylosing spondylitis (AS) is the prototypic inflamma-
tory spondyloarthritis with a peak onset between 20 to 30
years [1,2]. Extra-articular features of AS include inflam-
mation of the eyes, skin, bowels, and more rarely the lungs
and heart. There is a male preponderance as men are af-
fected 2 to 3 times more frequently than females [3,4].
Genetic factors are of major importance in susceptibility
to AS and, in fact, genetic epidemiological studies suggest
that AS represents one of the most heritable complex auto-
immune diseases with a heritability greater than 90% and a
sibling recurrence ratio of at least 52 [2-4]. HLA-B*27,* Correspondence: prahman@mun.ca
1Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NF,
Canada
Full list of author information is available at the end of the article
© 2013 Uddin et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orwhich was first recognized to be associated with AS in
1973, remains the strongest genetic association signal with
AS, and it is estimated that HLA-B*27 accounts for 23% of
the genetic heritability [2-4]. Despite this strong associ-
ation, only a small fraction (1-5%) of HLA-B*27 positive
individuals develop AS [2-4]. Recent genome-wide associ-
ation studies (GWAS) in several European populations and
in the Han Chinese population have identified up to 15
high priority genes including IL23R, RUNX3, KIF21B,
2p15, IL1R2, PTGER4, ERAP1, IL12B, CARD9, TNFR1/
LTBR, TBKBP1 [5]. These associations were primarily
reported based on single nucleotide polymorphisms (SNP)
analysis. Recently, an association study revealed the com-
plex interactions between the non-HLA gene, ERAP1, with
the HLA-B*27 gene [5,6]. However, the genetic risktd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genomic variants may contribute to the risk factor for AS.
The premise that CNVs contribute to disease patho-
genesis is supported by their capacity to disrupt gene ex-
pression and to interrupt functional pathways [7]. In
recent years, many CNVs have been associated with
complex diseases and the majority of these associations
were in autoimmune-mediated diseases, including rheu-
matoid arthritis, psoriasis, Crohn’s disease, and systemic
lupus erythematous [8-11]. Here, we report the first
validated CNV associated specifically with AS using
a custom genome-wide microarray in a well-defined
multiplex AS family.Results
Multiplex family
The quality control (QC) measures for the custom
microarray chip were very good as all samples exhibited
<0.25 DLRS. Approximately 1700 CNVs were detected
in each individual sample using our custom microarray.
Segregated gene-centric CNV analysis (i.e., a CNV that
consists of or overlaps with a gene) revealed that 56
CNVs are enriched in affected family members (at least
three) and absent in the unaffected family members.
Among these 56 CNVs, we have identified ten (9) gene
copy number variation regions (CNVRs) that segregate
with at least six (6) affected family members (Additional
file 1: Table S1). Our microarray analysis revealed mul-
tiple duplications within the UGT2B17 gene region that
segregate in the affected family members that is absent
in unaffected family members. One 7 kb duplication
(chr4:69423002–69430016) disrupts exon 3 of the
UGT2B17 gene and segregates with six AS affected fam-
ily members (Figure 1). The breakpoint encompassing
the UGT2B17 gene region was covered with probes
with 280 bp spacing, providing high resolution to detect
genomic aberrations. Validation of this targeted region
using real time QF-PCR demonstrated 100% concord-
ance with the microarray analysis (Figure 2). The real
time QF-PCR CNV call (>99% confidence) revealed that
affected family members carried two (2) copies of the
UGT2B17 gene, whereas unaffected members carried a
single copy. Eight (8) of the ten (10) family members
were HLA-B27 positive including and all six affected
family members that carried two (2) copies of the
UGT2B17 gene.Disease prevalence (case control studies)
In the case–control cohorts, real time QF-PCR analysis
targeting the identical CNVR (from family analysis) re-
vealed the presence of three (3) alleles (0 copy - homo-
zygous deletion, 1 copy - heterozygous deletion, and 2
copies) within this population for the UGT2B17 gene.In the Newfoundland population, the frequency of the
three alleles was 0.13, 0.51, and 0.35 for 0, 1 and 2 copies
in controls, respectively. The frequency of two (2) copies
of the UGT2B17 gene CNV was 0.41 in the Newfound-
land AS cases and 0.35 in the Newfoundland controls
(OR = 1.26 (95% CI:0.99-1.59); p = 0.05). The frequency
of two (2) copies of the UGT2B17 gene in the Alberta
population was 0.40 and 0.39 for AS cases and controls,
respectively (OR = 1.05 (95% CI:0.83-1.33); p = 0.71)
(Table 1). The association analysis for the combined co-
hort (Newfoundland and Alberta population) revealed
two (2) copies of the UGT2B17 gene with a frequency of
0.40 and 0.37, for the cases and controls, respectively
(association significance p = 0.09).
Discussion
Copy number variations are increasingly being recog-
nized in complex autoimmune diseases as they are cap-
able of altering gene dosage and consequently affect
gene function [12]. The contribution of CNVs in AS
pathogenesis remains to be systematically evaluated. The
primary goal of this study was to identify functionally
relevant CNVs segregating within a multiplex AS family
and then subsequently determine the allele frequencies
of CNVs in multiple case–control cohorts. The genome-
wide CNV analysis performed in this study revealed that
increased copy number of the UGT2B17 gene is a po-
tential risk factor for AS.
Given that UGT2B17 is a functional gene encoding an
enzyme that metabolizes steroid hormones including
testosterone and selected xenobiotics [13-16], it repre-
sents an excellent candidate gene for susceptibility to
AS. A gene-dosage effect is present as this CNV is asso-
ciated with urine testosterone level, male insulin sensi-
tivity, fat mass, and prostate-cancer risk (as summarized
by Xue) [13]. Importantly, copies of the UGT2B17 gene
have recently been associated with osteoporosis (includ-
ing hip fracture) [14]. The dose of the UGT2B17 gene
was significantly associated with bone mineral density,
cortical thickness, and buckling ratio. These results sup-
port the role of UGT2B17 CNVs in the pathogenesis of
osteoporosis. Although AS is characterized by new bone
formation, osteoporosis is a well recognized complica-
tion of AS and the risk of clinical vertebral fractures is
increased in AS patients [17,18]. This complexity with
respect to genotype-phenotype correlation requires fur-
ther investigation.
From an evolutionary perspective, the UGT2B17 gene
in humans is highly stratified which renders it more
likely to be associated with disease. The deletion allele
(i.e., 0 copies) frequency varies significantly among pop-
ulations. For example, the frequency of the deletion
allele is approximately 0.15 in Europeans, ~0.22 in
Africans, and ~0.80-0.90 in Asians [7,13]. In contrast,
Figure 1 a) A three generational pedigree comprising 13 individuals. DNA was available only for the individuals with an identification
number (Ids). The affected family members are indicated by solid colors and member 002 has systemic lupus erythematous (SLE). b) The
microarray intensity values for the UGT2B17 region are indicated below the pedigree for each of the family members. Each green/red point
represents the probe intensities, the cyan rectangle represents the gene location, and horizontal dark blue rectangles represent duplications
detected by the genome-wide analysis of CNVs.
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rare in Asian populations (~0.01-0.03), ~0.30-0.40 (re-
ports with varying frequencies) in Europeans, and ~0.60
in African populations.
In this study, two copies of the UGT2B17 gene clearly
segregates within a large well-defined AS multiplex fam-
ily. Given the nature and proposed function of the
UGT2B17 gene [19,20], the UGT2B17 CNV may con-
tribute to susceptibility for AS within this family.
Conflicting results were obtained regarding the excess
prevalence of this CNV in large uniplex AS cohorts. A
trend was observed in the cohort from Newfoundland.
However, this was not replicated in the Alberta cohort.In this study, the deletion (i.e., 0 copies) frequency of the
UGT2B17 gene in the Newfoundland population is con-
sistent with the Alberta population. There was a notice-
able frequency difference between the Alberta (0.51) and
Newfoundland (0.46) populations for a single copy of
the UGT2B17 gene. This stratification may represent a
contributing factor for the lack of association.
The analysis of CNVs within multiplex families pro-
vides a unique opportunity to detect variants that may
be family-specific. There are multiple reports in other
complex diseases where family specific CNVs manifest
with the disease [21]. Although it is a difficult task to ob-
tain more multi-generational pedigrees to follow up the
Figure 2 UGT2B17 gene copy number validation using real time QF-PCR on family members and three reference HapMap samples.
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investigated family suggests that segregation analysis into
multiple multi-generation pedigrees is promising. Thus, it
is important to assess other large multiplex families to de-
termine if this CNV may be a cause of familial AS.
Conclusions
This is study applied a custom designed genome-wide
microarray to investigate a large multiplex AS family re-
vealed segregation of the UGT2B17 gene CNV among
all affected family members. The association of the
UGT2B17 CNV with AS is particularly interesting given
the recent association of this CNV with osteoporosis
and the proposed function as it encodes a key enzyme
that inhibits androgens. This result provides a basis for
further exploration on the role of CNV in AS pathogen-
esis. Further replication is required for the marginal sig-




A multiplex AS family from Newfoundland was identi-
fied for this study. All members of the multiplex family
were “native Newfoundlanders” of North European an-
cestry. Ten (10) members from this large family partici-
pated in the study. Each individual was assessed
clinically including imaging studies. Six (6) of the ten
(10) family members had AS, as defined by the 1984
modified New York criteria, while the remaining familyTable 1 UGT2B17 gene CNV association in ankylosing spondy






285 controlsmembers were not affected. Informed consent for par-
ticipation in the study was obtained from participants or,
where participants are children, a parent or guardian.
After consent was obtained, all participating family
members had their DNA collected. All samples involving
human subjects reported in this manuscript have been
approved by the Memorial University of Newfoundland
Human Investigation Committee.
Case–control cohorts
DNA was obtained from two (2) well-defined AS co-
horts from the Newfoundland and Alberta populations.
All cases and controls were of North European ancestry.
We assessed 298 AS cases satisfying the modified New
York criteria and 299 ethnically-matched controls from
a homogenous population of Newfoundland. The second
cohort consisted of 289 AS cases satisfying the modified
New York criteria and 285 ethnically-matched controls
from Alberta.
Custom microarray
We designed a customized genome-wide microarray
based on genomic hotspot breakpoints previously identi-
fied [22]. The targeted regions are prone to produce
CNVs due to their structural architecture (i.e. presence
of segmental duplication, dose sensitive genes etc.). The
custom design tiling microarray consisted of 2 × 1 mil-
lion probes covering the genome with a mean spacing of
280 bp. Prior to CNV analysis, QC measures were ap-
plied and the derivative of log ratio spread (DLRS) <0.25litis
Healthy controls OR (95% CI) P value
0.35 1.26(0.99-1.59) <0.05
0.39 1.05(0.83-1.33) <0.71
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the built-in Aberration Detection Method-2 (ADM-2)
algorithm DNA Analytics v.4.0.85 (Agilent Technolo-
gies) using the following criteria: 1) at least 5 probes for
a CNV call on GC-corrected intensity; 2) nested filter
was set to 2; and 3) log intensity >0.25 for duplication
and <−0.25 for deletion. A custom script was applied to
detect gene-enriched CNVs (i.e., overlaps with or con-
stitutes a gene) that segregate (at least three cases)
within affected AS family members and absent in the
unaffected family members.QF-PCR
To validate the CNV encompassing the UGT2B17
(UDP glucuronosyltransferase 2 family, polypeptide
B17) gene in the family members and in the case–con-
trol cohorts, copy number estimation of the UGT2B17
gene was performed using the Taqman copy number
assay Hs03185327_cn (Life Technologies) using the
manufacturer’s recommended protocol. The assay was
performed in quadruplicate using 10ng genomic DNA
for each sample in a 96-well plate. The 10 μl reaction
mix consisted of 2 μl of 2× Taqman Genotyping Master
Mix (Life Technologies), 0.5 μl of 20× copy number
assay (described above), 0.5 μl of TaqMan RNAse P
Copy Number Reference Assay (Life Technologies, part
4403326), 2 μl of water, and 2 μl of 5 ng/μl genomic
DNA. Cycling conditions for the reaction were 95°C for
10 min, followed by 40 cycles of 95°C for 15 sec and
60°C for 1 min. Samples were analyzed using the ViiA™
7 Real-Time PCR System (Life Technologies) and ana-
lyzed using CopyCaller Software (Life Technologies, PN
4412907). Three reference (calibrator) DNA HapMap
samples (NA10851, NA15510 and NA07048 (Coriell In-
stitute)) plus one non-template control were included
with the test samples. Fisher exact test was performed
to determine association of the UGT2B17 gene copy
number with AS in our case–control data.Additional file
Additional file 1: Table S1. A list of gene-containing CNVs that
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